{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:55:46Z","timestamp":1790916946924,"version":"4.1.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Monitoring treatment response in extrapulmonary tuberculosis (EPTB) remains challenging due to limited microbiological accessibility and the lack of validated biomarkers. [18F]FDG positron emission tomography\/computed tomography [(18F)FDG-PET\/CT] enables assessment of metabolic disease activity and has been explored in infectious diseases, but evidence supporting its use in EPTB is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a prospective observational study including adults diagnosed with EPTB at a tertiary referral center in Denmark between 2016 and 2018. Participants underwent baseline and follow-up [18F]FDG-PET\/CT imaging after completion of the intensive treatment phase. Clinical data and laboratory parameters, including C-reactive protein (CRP), hemoglobin, leukocytes, albumin, and alanine aminotransferase were collected at baseline and during follow-up. Changes in standardized uptake values (SUVmax) and laboratory markers were analyzed descriptively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventeen patients were included. Metabolically active disease was detected in all participants at baseline. Most patients (11 out of 14) demonstrated a reduction in lesion number and SUVmax at follow-up, indicating a metabolic response to therapy. However, persistent [18F]FDG uptake was observed in a subset of patients (3 out of 14). Median CRP levels declined from 12\u2005mg\/L (range: 0.3\u2013190) at baseline to 3.6\u2005mg\/L (range: 0.9\u201320) at week 8 and remained low thereafter, broadly paralleling PET\/CT findings. In several cases, residual metabolic activity did not result in treatment prolongation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Serial [18F]FDG-PET\/CT demonstrated changes in metabolic activity during treatment with reductions in lesion number and SUVmax in most patients. However, SUVmax reflects focal metabolic activity rather than total disease burden, and persistent uptake after the intensive treatment phase was observed in some patients. Larger prospective studies incorporating standardized response criteria and volumetric PET measures are needed before [18F]FDG-PET\/CT can be implemented as a routine biomarker for treatment response in EPTB.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1908921","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:38:27Z","timestamp":1790915907000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessing early therapeutic response in extrapulmonary tuberculosis using [18F]FDG-PET\/CT imaging"],"prefix":"10.3389","volume":"13","author":[{"given":"Dev","family":"Kartan","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Odense University Hospital","place":["Odense, Denmark"]},{"name":"Lewis Katz School of Medicine","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziba Ahangarani","family":"Farahani","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Odense University Hospital","place":["Odense, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Hess","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Odense University Hospital","place":["Odense, Denmark"]},{"name":"Research Unit of Nuclear Medicine, Department of Clinical Research, University of Southern Denmark, Odense , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke","family":"S\u00f8ndergaard","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Odense University Hospital","place":["Odense, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oke","family":"Gerke","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Odense University Hospital","place":["Odense, Denmark"]},{"name":"Research Unit of Nuclear Medicine, Department of Clinical Research, University of Southern Denmark, Odense , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isik Somuncu","family":"Johansen","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Odense University Hospital","place":["Odense, Denmark"]},{"name":"Research Unit of Infectious Diseases, Department of Clinical Research, University of Southern Denmark, Odense , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"B1","first-page":"53","article-title":"History of BCG vaccine","volume":"8","author":"Luca","year":"2013","journal-title":"Maedica (Buchar)"},{"key":"B2","volume-title":"Global Tuberculosis Report 2025","year":"2025"},{"key":"B3","article-title":"Tuberculosis","volume-title":"Annual Epidemiological Report for 2022","year":"2024"},{"key":"B4","doi-asserted-by":"publisher","first-page":"20432","DOI":"10.2807\/ese.18.12.20432-en","article-title":"Challenges in diagnosing extrapulmonary tuberculosis in the European union, 2011","volume":"18","author":"Solovic","year":"2013","journal-title":"Euro Surveill"},{"key":"B5","doi-asserted-by":"publisher","first-page":"107601","DOI":"10.1016\/j.rmed.2024.107601","article-title":"Diagnosis of extra pulmonary tuberculosis: an update on novel diagnostic approaches","volume":"225","author":"Jain","year":"2024","journal-title":"Respir Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"ofz388","DOI":"10.1093\/ofid\/ofz388","article-title":"Extrapulmonary tuberculosis in Denmark from 2009 to 2014; characteristics and predictors for treatment outcome","volume":"6","author":"Holden","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"20431","DOI":"10.2807\/ese.18.12.20431-en","article-title":"Extrapulmonary tuberculosis in the European union and European economic area, 2002 to 2011","volume":"18","author":"Sandgren","year":"2013","journal-title":"Euro Surveill"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e0243945","DOI":"10.1371\/journal.pone.0243945","article-title":"Epidemiology and the diagnostic challenge of extra-pulmonary tuberculosis in a teaching hospital in Ethiopia","volume":"15","author":"Arega","year":"2020","journal-title":"PLoS One"},{"key":"B9","doi-asserted-by":"publisher","first-page":"155499","DOI":"10.1016\/j.cyto.2021.155499","article-title":"Host biomarkers for monitoring therapeutic response in extrapulmonary tuberculosis","volume":"142","author":"Ambreen","year":"2021","journal-title":"Cytokine"},{"key":"B10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.4046\/trd.2015.78.2.47","article-title":"Diagnosis and treatment of extrapulmonary tuberculosis","volume":"78","author":"Lee","year":"2015","journal-title":"Tuberc Respir Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s11604-012-0076-5","article-title":"The role of FDG PET-CT in the therapeutic evaluation for HNSCC patients","volume":"30","author":"Kawabe","year":"2012","journal-title":"Jpn J Radiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1097\/RLU.0000000000002968","article-title":"18F-FDG PET\/CT in tuberculosis: can interim PET\/CT predict the clinical outcome of the patients?","volume":"45","author":"Sood","year":"2020","journal-title":"Clin Nucl Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1901959","DOI":"10.1183\/13993003.01959-2019","article-title":"PET\/CT features of extrapulmonary tuberculosis at first clinical presentation: a cross-sectional observational 18F-FDG imaging study across six countries","volume":"55","author":"Bomanji","year":"2020","journal-title":"Eur Respir J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s15010-026-02750-w","article-title":"Whole-body PET\/CT reveals systemic dissemination in spinal tuberculosis: findings from the spinal TB X cohort","volume":"54","author":"Scherer","year":"2026","journal-title":"Infection"},{"key":"B15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40336-017-0259-2","article-title":"Value of FDG-PET\/CT for treatment response in tuberculosis: a systematic review and meta-analysis","volume":"6","author":"Sj\u00f6lander","year":"2018","journal-title":"Clin Transl Imaging"},{"key":"B16","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13550-016-0228-1","article-title":"The role of FDG-PET\/CT in preoperative staging of sentinel lymph node biopsy-positive melanoma patients","volume":"6","author":"Frary","year":"2016","journal-title":"EJNMMI Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3390\/jpm11020133","article-title":"PET\/CT imaging for personalized management of infectious diseases","volume":"11","author":"Pijl","year":"2021","journal-title":"J Pers Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1007\/s00259-020-04888-7","article-title":"Sequential 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) scan findings in patients with extrapulmonary tuberculosis during the course of treatment-a prospective observational study","volume":"47","author":"Bomanji","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B20","doi-asserted-by":"publisher","first-page":"160","DOI":"10.4103\/ortho.IJOrtho_224_18","article-title":"Evaluation of healed status in tuberculosis of spine by fluorodeoxyglucose-positron emission tomography\/computed tomography and contrast magnetic resonance imaging","volume":"53","author":"Mittal","year":"2019","journal-title":"Indian J Orthop"},{"key":"B21","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/RLU.0000000000002187","article-title":"Prospective serial FDG PET\/CT during treatment of extrapulmonary tuberculosis in HIV-infected patients: an exploratory study","volume":"43","author":"Martin","year":"2018","journal-title":"Clin Nucl Med"},{"key":"B22","doi-asserted-by":"crossref","first-page":"444","DOI":"10.2967\/jnumed.117.195628","article-title":"18F-FDG PET-CT for monitoring treatment response in extra-pulmonary tubercular infections","volume":"59","author":"Piccardo","year":"2018","journal-title":"J Nucl Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e187","DOI":"10.1097\/RLU.0000000000001102","article-title":"18F-FDG PET\/CT in the initial assessment and for follow-up in patients with tuberculosis","volume":"41","author":"Stelzmueller","year":"2016","journal-title":"Clin Nucl Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13550-020-0591-9","article-title":"Quantitative 18F-FDG PET-CT scan characteristics correlate with tuberculosis treatment response","volume":"10","author":"Malherbe","year":"2020","journal-title":"EJNMMI Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adt5626","article-title":"Clinical testing of drug treatment shortening in patients with TB using PET\/CT imaging of lung lesions","volume":"18","author":"Malherbe","year":"2026","journal-title":"Sci Transl Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s40336-014-0062-2","article-title":"A brief overview of novel approaches to FDG PET imaging and quantification","volume":"2","author":"Hess","year":"2014","journal-title":"Clin Transl Imaging"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1007\/s00259-014-2826-3","article-title":"FDG PET\/CT methodology for evaluation of treatment response in lymphoma: from \u201cgraded visual analysis\u201d and semiquantitative SUVmax\u201d to global disease burden assessment","volume":"41","author":"Basu","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1908921\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:38:32Z","timestamp":1790915912000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1908921\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":27,"alternative-id":["10.3389\/fmed.2026.1908921"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1908921","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"article-number":"1908921"}}